COMMUNIQUÉS West-GlobeNewswire

Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
30/04/2026
Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, April 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Srishti Gupta, MD, MPP, MPhil, as an Independent Director at the upcoming [...]
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
30/04/2026
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi® 1 €22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, [...]
Valneva Announces the Successful Completion of an €84 million Reserved Offering
30/04/2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine [...]
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
30/04/2026
OSE a abordé 2026 avec un plan stratégique clair à 3 ans, axé sur plusieurs catalyseurs à court terme pour lusvertikimab et Tedopi® 1 Trésorerie de 22,7 millions d’euros au 31 décembre 2025 et 17,0 millions d’euros au [...]
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
30/04/2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
30/04/2026
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited ( [...]
Avalyn Announces Pricing of Upsized Initial Public Offering
30/04/2026
BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare [...]
Vaccinex Reports 2025 Annual Financial Results
30/04/2026
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and [...]
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
29/04/2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
29/04/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through innovative, [...]
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
29/04/2026
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on [...]
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
29/04/2026
RECELL GO ® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets RECELL GO is AVITA Medical’s next-generation system that automates and standardizes the preparation [...]
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
29/04/2026
SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
29/04/2026
RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
LogicMark, Inc. to Announce First Quarter 2026 Financial Results on May 13, 2026
30/04/2026
LOUISVILLE, Ky., April 29, 2026 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK), a provider of emergency response systems, health communications devices, and technology for the growing personal safety and care economy, [...]
Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026
29/04/2026
Webcast Scheduled for Wednesday, May 6 at 8:00 a.m. Eastern CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development [...]
MIMEDX Announces First Quarter 2026 Operating & Financial Results
29/04/2026
Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 (GLOBE [...]
INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
29/04/2026
SARASOTA, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company focused on expanding access to advanced reproductive treatment [...]
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
29/04/2026
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Pages